Literature DB >> 26022172

Genetics and emerging treatments for Duchenne and Becker muscular dystrophy.

Nicolas Wein1, Lindsay Alfano2, Kevin M Flanigan3.   

Abstract

Mutations in the DMD gene result in Duchenne or Becker muscular dystrophy due to absent or altered expression of the dystrophin protein. The more severe Duchenne muscular dystrophy typically presents around ages 2 to 5 with gait disturbance, and historically has led to the loss of ambulation by age 12. It is important for the practicing pediatrician, however, to be aware of other presenting signs, such as delayed motor or cognitive milestones, or elevated serum transaminases. Becker muscular dystrophy is milder, often presenting after age 5, with ambulation frequently preserved past 20 years and sometimes into late decades.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Becker; DMD gene; Duchenne; Dystrophin; Exon skipping; Gene therapy; Muscular dystrophy; Nonsense suppression

Mesh:

Substances:

Year:  2015        PMID: 26022172     DOI: 10.1016/j.pcl.2015.03.008

Source DB:  PubMed          Journal:  Pediatr Clin North Am        ISSN: 0031-3955            Impact factor:   3.278


  23 in total

1.  Comparison of Serum rAAV Serotype-Specific Antibodies in Patients with Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Inclusion Body Myositis, or GNE Myopathy.

Authors:  Deborah A Zygmunt; Kelly E Crowe; Kevin M Flanigan; Paul T Martin
Journal:  Hum Gene Ther       Date:  2016-12-29       Impact factor: 5.695

Review 2.  Dystrophin and the two related genetic diseases, Duchenne and Becker muscular dystrophies.

Authors:  Elisabeth Le Rumeur
Journal:  Bosn J Basic Med Sci       Date:  2015-07-20       Impact factor: 3.363

3.  N-terminal α Dystroglycan (αDG-N): A Potential Serum Biomarker for Duchenne Muscular Dystrophy.

Authors:  Kelly E Crowe; Guohong Shao; Kevin M Flanigan; Paul T Martin
Journal:  J Neuromuscul Dis       Date:  2016-05-27

4.  Clinical Utility Gene Card for: Becker muscular dystrophy.

Authors:  David Coote; Mark R Davis; Macarena Cabrera; Merrilee Needham; Nigel G Laing; Kristen J Nowak
Journal:  Eur J Hum Genet       Date:  2018-02-21       Impact factor: 4.246

5.  Eosinophils Do Not Drive Acute Muscle Pathology in the mdx Mouse Model of Duchenne Muscular Dystrophy.

Authors:  Albert C Sek; Ian N Moore; Margery G Smelkinson; Katherine Pak; Mahnaz Minai; Roberta Smith; Michelle Ma; Caroline M Percopo; Helene F Rosenberg
Journal:  J Immunol       Date:  2019-05-29       Impact factor: 5.422

6.  Structural Basis of Neuronal Nitric-oxide Synthase Interaction with Dystrophin Repeats 16 and 17.

Authors:  Anne-Elisabeth Molza; Khushdeep Mangat; Elisabeth Le Rumeur; Jean-François Hubert; Nick Menhart; Olivier Delalande
Journal:  J Biol Chem       Date:  2015-09-16       Impact factor: 5.157

7.  Cathepsin S Contributes to the Pathogenesis of Muscular Dystrophy in Mice.

Authors:  Andoria Tjondrokoesoemo; Tobias G Schips; Michelle A Sargent; Davy Vanhoutte; Onur Kanisicak; Vikram Prasad; Suh-Chin J Lin; Marjorie Maillet; Jeffery D Molkentin
Journal:  J Biol Chem       Date:  2016-03-10       Impact factor: 5.157

8.  Beware of missed diagnosis in patients with multiple genetic diseases: a case report.

Authors:  Detong Guo; Xuemei Li; Nan Liu; Xiaoli Yu; Jianbo Shu; Wenchao Sheng; Dong Li; Chunquan Cai
Journal:  BMC Pediatr       Date:  2022-07-20       Impact factor: 2.567

9.  CUGC for Duchenne muscular dystrophy (DMD).

Authors:  David J Coote; Mark R Davis; Macarena Cabrera; Merrilee Needham; Nigel G Laing; Kristen J Nowak
Journal:  Eur J Hum Genet       Date:  2018-01-12       Impact factor: 4.246

10.  Gait characterization in golden retriever muscular dystrophy dogs using linear discriminant analysis.

Authors:  Bodvaël Fraysse; Inès Barthélémy; El Mostafa Qannari; Karl Rouger; Chantal Thorin; Stéphane Blot; Caroline Le Guiner; Yan Chérel; Jean-Yves Hogrel
Journal:  BMC Musculoskelet Disord       Date:  2017-04-12       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.